Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05071209 · ClinicalTrials.gov registry record · Phase 1
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
A Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 20
- Study locations
NCT05071209: Active Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma, sponsored by National Cancer Institute (NCI).
NCT05071209 is a Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 31 participants, below the 64-participant average among 59 other Refractory Malignant Solid Neoplasm trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05071209, a Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I/II trial tests the safety, best dose, and whether elimusertib works in treating patients with solid tumors that have come back (relapsed) or does not respond to treatment (refractory). Elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Frequency (%) of patients experiencing a cycle 1 dose limiting toxicity among toxicity-evaluable patients stratified by dose level during the dose escalation part of the study (Part A).
Conditions Studied
Interventions
- DRUG Elimusertib
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Children's Hospital of Orange County - Orange
- UCSF Medical Center-Mission Bay - San Francisco
Missouri
- Children's Mercy Hospitals and Clinics - Kansas City
- Washington University School of Medicine - St Louis
New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Alabama
- Children's Hospital of Alabama - Birmingham
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- Johns Hopkins All Children's Hospital - St. Petersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-12-22 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
What the registry record for NCT05071209 still lists
NCT05071209 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 64-participant average among 59 other Refractory Malignant Solid Neoplasm trials with a reported enrollment target (52% lower).
The record links to 8 conditions, with Refractory Malignant Solid Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Elimusertib is the first listed.
NCT05071209 names 20 study sites across 15 states, led by California, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT05071209 about?
NCT05071209 is a clinical study titled "Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors". This phase I/II trial tests the safety, best dose, and whether elimusertib works in treating patients with solid tumors that have come back (relapsed) or does not respond to treatment (refractory). Elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT05071209?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2021-12-22. Estimated completion is 2026-03-31.
What conditions does trial NCT05071209 study?
This clinical trial studies the following conditions: Refractory Malignant Solid Neoplasm, Refractory Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Ewing Sarcoma, Recurrent Lymphoma.
What interventions are being tested in trial NCT05071209?
The interventions under investigation include: Elimusertib (DRUG).
Who is sponsoring clinical trial NCT05071209?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05071209 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05071209's enrollment target sits among peer trials
31 44th of 59 higher than 16 of 59 other Refractory Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
RECRUITING · Phase 1
-
Studying TAK-243 in Patients With Advanced Cancer
RECRUITING · Phase 1
-
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
RECRUITING · Phase 1
-
AOH1996 for the Treatment of Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI